TrialEuropean journal of clinical pharmacology2018

Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites.

Hye-In Lee et al.PubMed ↗Publisher ↗

No numbers read from the abstract.